Study #2026-0130
A Phase 2, Single-Arm, Multicenter, Open-Label Study Of Zanzalintinib In Participants With Recurrent Or Progressive Meningioma
MD Anderson Study Status
Enrolling
Treatment Agent
Zanzalintinib
Description
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Meningioma
Study phase:
Phase II
Physician name:
Carlos Kamiya Matsuoka
Department:
Neuro-Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.